Biologics CDMO Market Size to Surpass USD 96.85 Billion by 2035 | CAGR 10.7%
Published : 09 Nov 2026
Author : Lucas Hoffmann
What is the Biologics CDMO Market Size?
The global biologics CDMO market size was valued at USD 34.26 billion in 2025 and is anticipated to surpass around USD 96.85 billion by 2035 while expanding at a CAGR of 10.7% during the forecast period 2026 to 2035. The expanding biologics pipeline, rising demand for targeted therapies, and growing complexity of drug manufacturing are strengthening the role of contract development and manufacturing organizations (CDMOs). Pharmaceutical companies are increasingly outsourcing specialized production, analytical testing, and process development to access advanced capabilities, manage capital requirements, and accelerate commercial manufacturing.
Biologics CDMO Market Overview: The Manufacturing Backbone Behind Modern Biologic Therapies
Biologics have transformed treatment approaches across oncology, autoimmune disorders, metabolic diseases, and several other therapeutic areas. Unlike conventional small-molecule drugs, biologics are produced using living systems and require specialized manufacturing processes, tightly controlled production environments, and extensive quality testing. This complexity has made CDMOs important partners for pharmaceutical and biotechnology companies at different stages of drug development.
Biologics CDMOs provide services ranging from cell-line development and process optimization to drug substance manufacturing, analytical testing, quality control, fill-and-finish, and commercial-scale production. Their capabilities allow drug developers to access specialized infrastructure without having to build and maintain every manufacturing function internally.
Biologics CDMO Market Segmental Outlook: Where Is Manufacturing Demand Concentrated?
| Segmentation | Leading segment | Market share (2025) | Growth opportunity |
|---|---|---|---|
| By service type | Contract manufacturing drug substance | 52% | Analytical, QC, and other services: 11.8% CAGR |
| By product type | Monoclonal antibodies, including bispecifics | 56% | ADCs and bioconjugates: 15.9% CAGR |
| By expression system | Mammalian expression systems | 76% | Other expression systems: 12.7% CAGR |
| By manufacturing technology | Stainless-steel manufacturing | 60% | Single-use share projected to rise from 40.0% in 2025 to 53.0% by 2035 |
| By development stage | Commercial-stage manufacturing | 62% | Commercial-stage manufacturing: 11.1% CAGR |
| By biologic type | Innovator biologics | 80% | Biosimilars: 13.6% CAGR |
| By therapeutic application | Oncology | 42% | Metabolic and endocrine applications: 13.5% CAGR |
| By end user | Large pharmaceutical companies | 48% | Small and emerging biotechnology companies: 12.1% CAGR |
Where the Next Wave of CDMO Opportunities Is Emerging
1. ADC and bioconjugate manufacturing
The development of antibody-drug conjugates is creating demand for specialized manufacturing capabilities that combine biologic production with conjugation processes. CDMOs able to manage complex production workflows, analytical characterization, and quality requirements can pursue opportunities in this expanding category.
2. Single-use manufacturing facilities
The shift toward flexible production models creates opportunities for CDMOs investing in single-use bioreactors, disposable assemblies, and integrated manufacturing platforms. These technologies can support multiproduct operations and help facilities respond to changing client demand.
3. Outsourcing by emerging biotechnology companies
Early-stage and emerging biotech firms often need external support well before a therapy reaches commercial production. CDMOs offering integrated development, analytical, clinical manufacturing, and scale-up services can establish relationships early in the drug development process.
4. Biosimilar development and manufacturing
As biosimilar pipelines expand, manufacturers will require partners with expertise in process development, analytical comparability, quality control, and commercial production. This creates opportunities for CDMOs serving companies seeking cost-efficient biologic manufacturing.
Regional Outlook
North America Biologics CDMO Market: A Strong Base of Biopharmaceutical Innovation
North America dominated the biologics CDMO market with a 38.0% share in 2025, generating USD 13.02 billion in revenue. The region benefits from a well-established biopharmaceutical industry, significant research and development investment, and a strong presence of biotechnology companies developing advanced therapies.
The United States is the primary contributor to regional demand, supported by its pharmaceutical manufacturing ecosystem, biotechnology funding, and concentration of clinical-stage and commercial biologic programs. Drug developers increasingly rely on CDMOs for specialized manufacturing, analytical testing, and capacity expansion as biologic pipelines become more complex.
The region also benefits from established regulatory expertise, experienced technical workforces, and advanced manufacturing infrastructure. These factors support demand for monoclonal antibody production, ADC manufacturing, mammalian expression systems, and commercial-scale biologics services.
Asia-Pacific Biologics CDMO Market: A Manufacturing Hub With Strong Growth Potential
Asia-Pacific is projected to be the fastest-growing regional market, registering a CAGR of 12.9% from 2026 to 2035. The region accounted for 27.0% of the global market in 2025, generating USD 9.25 billion in revenue, and is projected to reach USD 31.96 billion by 2035.
Growth is supported by expanding biopharmaceutical manufacturing capabilities, rising investment in biotechnology, and increasing demand for cost-efficient production services. China, India, South Korea, and Japan are strengthening their positions through investments in biologics facilities, research capabilities, and specialized manufacturing infrastructure.
Country Markets to Watch
- United States: The United States remains a major biologics development and manufacturing market, supported by biotechnology investment, pharmaceutical research, and demand for advanced therapies. Its established CDMO ecosystem creates opportunities across monoclonal antibodies, ADCs, analytical testing, and commercial manufacturing.
- China: China's expanding biotechnology industry and investments in biologics manufacturing are supporting demand for contract development and production services. Growth in monoclonal antibodies, biosimilars, and advanced biologic therapies is creating opportunities for domestic and international CDMOs.
- India: India's pharmaceutical manufacturing base, cost-competitive production environment, and growing biotechnology sector are supporting its role in outsourced biologics services. Investments in biologics infrastructure and biosimilar development are expected to create additional opportunities.
Biologics CDMO Market Competitive Landscape
Lonza Group AG, Samsung Biologics, Catalent, Inc., WuXi Biologics, Boehringer Ingelheim, Fujifilm Diosynth Biotechnologies, Thermo Fisher Scientific, AGC Biologics, Rentschler Biopharma, and KBI Biopharma are among the key players operating in the biologics CDMO market. These companies are strengthening their competitive positions through investments in manufacturing capacity, advanced biologics platforms, and integrated development and production services.
Segments Covered
By Service Type
- Contract Manufacturing – Drug Substance
- Contract Manufacturing – Drug Product / Fill-Finish
- Process Development
- Cell Line Development
- Analytical, Quality Control (QC) & Other Services
By Product Type
- Monoclonal Antibodies (Including Bispecifics)
- Antibody-Drug Conjugates (ADCs) & Bioconjugates
- Recombinant Proteins & Enzymes
- Vaccines
- Cell & Gene Therapies
- mRNA & Other Biologics
By Expression System
- Mammalian (CHO, HEK293, and Others)
- Microbial (Bacterial & Yeast)
- Others (Insect, Plant, and Cell-Free)
By Manufacturing Technology
- Stainless-Steel Bioreactors
- Single-Use Bioreactors
By Development Stage
- Clinical (Preclinical to Phase III)
- Commercial
By Biologic Type
- Innovator Biologics
- Biosimilars
By Therapeutic Application
- Oncology
- Immunology & Inflammation
- Infectious Diseases
- Metabolic & Endocrine
- Neurology
- Hematology
- Others (Ophthalmology, Rare Diseases, and Cardiovascular)
By End User
- Large Pharmaceutical Companies
- Mid-Size Pharmaceutical Companies
- Small & Emerging Biotech Companies
- Academic, Government & Other Clients
By Region
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East & Africa
Contact Us:
Mr. Richard Johnson
Acumen Research and Consulting
India: +91 8983225533